Skip to content

The effectiveness of using Prolia drug on bone density

The effectiveness of using Prolia drug on bone density in hemodialysis patients

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20191030045282N1
Enrollment
120
Registered
2020-06-12
Start date
2020-03-20
Completion date
Unknown
Last updated
2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone density.

Interventions

Intervention group: These people will intervene after a bone density measurement test and confirmation of osteoporosis, if there is conscious consent,Individuals receive subcutaneous doses of 60 mg o

Sponsors

Deputy of research and technology of Alborz university of medical sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: The patient should have informed consent to participate in the intervention The patient should be undergone hemodialysis courses The patient has a medical diagnosis of osteoporosis

Exclusion criteria

Exclusion criteria: The patient does not have conscious consent to participate in the intervention The patient does not have a medical diagnosis of osteoporosis The patient has a history of previous fractures

Design outcomes

Primary

MeasureTime frame
Bone density. Timepoint: The amount of bone density will be measured before the intervention and one month after the subcutaneous injection of the prolia drug. Method of measurement: Bone density measurement test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElahe Dolatshahipirooz

Alborz University of Medical Sciences

e.dolatshahi@abzums.ac.ir+98 26 3457 0030

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026